Patents Represented by Attorney, Agent or Law Firm Jan P. Brunelle
-
Patent number: 5514200Abstract: Concentrated phosphorus fertilizers are disclosed that comprise a buffered composition of an organic acid and salts thereof and a phosphorous-containing acid and salts thereof. The concentrated phosphorus fertilizers can be diluted with water of pH ranging from about 6.5 to about 8.5 at ratios of concentrate to water at about 1:40 to about 1:600 to result in a fertilizer having a pH in the range acceptable for foliar uptake of phosphorus.Type: GrantFiled: February 7, 1994Date of Patent: May 7, 1996Assignee: The Regents of the University of CaliforniaInventor: Carol J. Lovatt
-
Patent number: 5492825Abstract: This disclosure relates to two separate and distinct inward rectifier K.sup.+ channel expression products and the the genes which encode each expression product. The IRK1 gene (SEQ. ID NO: 1) encodes an inward rectifier K.sup.+ channel and the GIRK1 gene (SEQ. ID NO: 31) encodes a G protein coupled muscarinic K.sup.+ channel. The disclosure relates to the uses of these expression products, particularly in combination with identifying physiological processes mediated by these channels, such as regulation of heartbeat and insulin release and materials modulating or blocking same.Type: GrantFiled: August 6, 1993Date of Patent: February 20, 1996Assignee: The Regents of the University of CaliforniaInventors: Lily Y. Jan, Yuh N. Jan, Yoshihiro Kubo
-
Patent number: 5464754Abstract: A non-radioactive, spectrophotometric, microtiter plate assay for human cystolic phospholipase A.sub.2 (cPLA.sub.2) is described. The assay utilizes a novel synthetic thiol-phospholipid analog as a substrate. In one embodiment, the substrate is a phosphatidylcholine derivative with an arachidonoylthioester in the sn-2 position and an alkenyl-ether or alkenyl-ether in the sn-1 position. The alkyl-ether and the alkenyl-ether in the sn-1 position of the substrate ensures that the assay will only measure cPLA.sub.2 activity and will not be complicated by metabolism of the lysophospholipid product by the enzyme's and lysophospholypase activity.Type: GrantFiled: August 17, 1993Date of Patent: November 7, 1995Assignee: The Regents of the University of CaliforniaInventors: Edward A. Dennis, Laure J. Reynolds, Lin Yu
-
Patent number: 5449515Abstract: Therapeutic compositions and methods for the treatment of inflammation are disclosed. The compositions comprise at least one anti-inflammatory drug in combination with the lymphokine interleukin-4 (IL-4), which components interact synergistically in the treatmement of inflammation. Methods for the treatment of inflammation comprise administering to a subject in need of such treatment an effective amount of at least one anti-inflammatory drug and IL-4.Type: GrantFiled: July 14, 1992Date of Patent: September 12, 1995Assignee: University of MelbourneInventors: John A. Hamilton, Prudence H. Hart
-
Patent number: 5445942Abstract: Hydrolase enzymes are sensitively determined using novel substituted FAD substrates. The substituted FAD substrates are hydrolysed to FAD by the enzyme to be detected. The FAD is then combined with an apoenzyme to form a holoenzyme which is used to initiate a reaction that leads to a detectable product. When the hydrolase to be detected is phosphatase, the novel substrate is a phosphorylated derivative of FAD. A suitable apoenzyme is apo-glucose oxidase which provides exceptional sensitivity. Apo-D-amino acid oxidase, which is suitable for use in a "single pot" assay system, can also be used.Type: GrantFiled: January 13, 1993Date of Patent: August 29, 1995Assignee: London Biotechnology LimitedInventors: Brian R. Rabin, Stuart Harbron, Hendrikus J. Eggelte, Michael R. Hollaway, deceased, Ann Holloway, legal representative
-
Patent number: 5434046Abstract: This invention relates to DNA encoding drug resistance to cis-platin. The invention also includes expression products of, and vectors and hosts comprising the DNA sequence encoding cis-platin resistance. Also included are immunodiagnostic assays of cis-platin resistance and assays for screening materials having a modulating effect on DNA encoding the cis-platin resistance gene and on the expression product thereof. The invention is further directed to antagonists to the cis-platin resistance gene and the expression product thereof. Recombinant and pharmaceutical means making use of the cis-platin resistance gene and its expression product are also provided.Type: GrantFiled: March 8, 1993Date of Patent: July 18, 1995Assignee: The Regents of the University of CaliforniaInventors: Robert E. Enns, Stephen B. Howell
-
Patent number: 5429723Abstract: HOBr solution for biocidal treatment is produced by electrolysis of mixed chloride/bromide solution. The chloride: bromide molar ratio is greater than 4:1. The molar ratio and rate and period of electrolysis can be selected so as to result in high yield of HOBr, preferably over 90% of theory, and little or no residual HOCl. The process can suitably be carried out by recirculating the mixed halide electrolyte through an electrolytic cell for a time appropriate to achieve the desired result, and then discharging the solution to a receiving system.Type: GrantFiled: June 24, 1994Date of Patent: July 4, 1995Assignee: Cogent LimitedInventor: Alan Atkinson
-
Patent number: 5427919Abstract: The present invention provides compounds that function as hydrolytic enzyme inhibitors (inactivators) and substrates. These compounds are useful in assays to detect and measure levels of hydrolytic enzyme activity and are more particularly useful in treatment regimens for various disease states and conditions implicating the underlying specific hydrolytic enzyme. Examples of hydrolytic enzymes include, but are not limited to, phospholipases, lipases, esterases, proteases, etc.Type: GrantFiled: December 2, 1993Date of Patent: June 27, 1995Assignee: The Regents of the University of CaliforniaInventors: Edward A. Dennis, William N. Washburn
-
Patent number: 5403813Abstract: A controlled release agricultural composition comprising an aqueous dispersion of: 1) a water insoluble matrix comprising a viscous oil (i.e., a hydrocarbon crude oil or post-refining residual oil) selected from the group consisting of bitumen, abietic acid, ester derivatives of abietic acid, carboxylic acid containing materials, and carboxylic acid ester containing materials, and 2) at least one active ingredient, which has a melting point of less than 140.degree. C. and is soluble in the viscous oil matrix, selected from the group consisting of herbicides, insecticides, fungicides, and nematicides.Type: GrantFiled: January 18, 1993Date of Patent: April 4, 1995Assignee: Daratech Proprietary LimitedInventors: Gottfried Lichti, Anthony G. Flynn, Alexander Serban, Darren J. Park, William R. Jackson, Janine J. Kibblewhite, Paul A. Horne, Daryl K. Wood, Jin L. Chen
-
Patent number: 5384121Abstract: The present invention relates to a method for the extraction of sesquiterpene lactones from the plant Tanacetum parthenium specifically using polar organic solvents and the use of such extracts in pharmaceutical products. It has been found that by utilization of an extraction procedure in accordance with the current invention, a significantly greater amount of the sesquiterpene lactone parthenolide is extracted from Tanacetum parthenium than is the case when using petroleum spirit as the primary extractant, the solvent usually used in previous studies.Type: GrantFiled: July 8, 1993Date of Patent: January 24, 1995Assignee: Rhodes TechnologyInventor: Alan Rhodes
-
Patent number: 5354846Abstract: A non-toxic and non-cytolytic derivative of streptolysin O which retains at least one (preferably immunodominant) epitope is produced, and can be used especially in diagnostic tests for detecting of the presence of antibodies to Streptococcus pyogenes in a sample.Type: GrantFiled: June 8, 1993Date of Patent: October 11, 1994Inventor: Michael Kehoe
-
Patent number: 5352673Abstract: The present invention provides prodrugs that serve as useful therapeutics for various disease states and conditions mediated by underlying specific hydrolytic enzyme activity. The prodrugs hereof (additionally) impart a physiologically bioactive component thus providing prodrug compounds that are capable of imparting dual effect systemically.Type: GrantFiled: June 10, 1991Date of Patent: October 4, 1994Inventor: Edward A. Dennis
-
Patent number: 5308766Abstract: The present invention provides compounds that function as hydrolytic enzyme inhibitors (inactivators) and substrates. These compounds are useful in assays to detect and measure levels of hydrolytic enzyme activity and are more particularly useful in treatment regimens for various disease states and conditions implicating the underlying specific hydrolytic enzyme. Examples of hydrolytic enzymes include, but are not limited to, phospholipases, lipases, esterases, proteases, etc.Type: GrantFiled: June 10, 1991Date of Patent: May 3, 1994Assignee: The Regents of the University of CaliforniaInventors: Edward A. Dennis, William N. Washburn
-
Patent number: 5290700Abstract: A cell culture device is disclosed where cells are confined in a liquid medium within a cell culture space. The cell culture space is delimited by at least three selectively permeable walls. One wall is formed by a sheet of tubes and is permeable to fresh nutrient medium, the second wall is formed of a layer of capillaries and is permeable to gaseous fluids, and the third wall acts as a micron sieve that allows the passage of spent nutrient medium, but retains the cells within the cell culture space. The cell culture device makes it possible to produce culture products, continuously and in bulk over a long period of time.Type: GrantFiled: January 14, 1992Date of Patent: March 1, 1994Assignee: Bertin & Cie.Inventors: Patrick Binot, Dominique Cognard, Frederic Dufau, Jean Hache